Rising Demand For Gene Therapy Driving The Growth Of The Market Due To Advancements In Biotechnology And Targeted Treatments: A Significant Driver Propelling The Fatty Acid Oxidation Disorders (FAODs) Market In 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Fatty Acid Oxidation Disorders (FAODs) Market Size and Projected Growth Rate?
The market for fatty acid oxidation disorders (FAODs) has shown remarkable growth in recent times. It is projected to expand from a valuation of $9.55 billion in 2024 to $10.33 billion in 2025, which represents a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historical period include improved awareness, increasing incidences of rare and genetic disorders, rising number of approved products, escalated government interventions, and a surge in demand for orphan drugs.

Predictions indicate a robust expansion of the fatty acid oxidation disorders (FAODs) market in the coming years, with an expected value of $13.99 billion in 2029 and a compound annual growth rate (CAGR) of 7.9%. The surge in this projected period is accredited to the escalating demand for enduring bio-products, the rise in personalized medicinal uptake, the early detection of FAODs, a boost in funding for research and development, and an intensified focus on improving long-term outcomes. The forecast period is set to witness major trends including the introduction of telehealth facilities, the application of artificial intelligence in diagnostic procedures and drug exploration, progress in genetic testing technologies, and a transition towards patient-oriented care models.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21964

What Are the Major Segments in the Fatty Acid Oxidation Disorders (FAODs) Market?
The fatty acid oxidation disorders (FAODs) market covered in this report is segmented -

1) By Type: Long Chain, Short Chain
2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types
3) By Route of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores
5) By End User: Hospitals, Clinics, Pharmaceutical Companies

Subsegments:

1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21964&type=smp

What Are The Driving Fatty Acid Oxidation Disorders (FAODs) Market Evolution?
The growing necessity for gene therapy is likely to drive the expansion of the fatty acid oxidation disorders (FAODs) market. Gene therapy, which is a medical process that alters or substitutes faulty genes in order to prevent or treat diseases, is witnessing rising demand due to its capacity to address the root genetic causes of genetic disorders, cancer, and rare diseases. This has resulted in considerable progress and investment in biotechnology. By delivering functional genes, gene therapy aims to rectify metabolic shortcomings associated with fatty acid oxidation disorders and enhance energy production, while preventing disease complications. For instance, in April 2024, the American Society of Gene & Cell Therapy, a US-based entity for gene and cell therapy, reported that the number of gene therapies in Phase III clinical trials saw a 10% rise in the fourth quarter, representing the first quarter-on-quarter growth of its kind since the third quarter of 2022. Consequently, the escalating demand for gene therapy is fuelling the expansion of the fatty acid oxidation disorders (FAODs) market.

Which Firms Dominate The Fatty Acid Oxidation Disorders (FAODs) Market Segments?
Major companies operating in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Frères SA, Dr Reddy's Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, NB Group Co Ltd.

What Trends Are Expected to Dominate the Fatty Acid Oxidation Disorders (FAODs) Market in the Next 5 Years?
Leading firms in the fatty acid oxidation disorders (FAODs) market are concentrating on creating innovative solutions like peroxisome proliferator-activated receptor delta (PPARd) agonists to bolster metabolic control and boost treatment results for FAOD patients. A PPARd agonist is a compound that activates the PPARd receptor, playing a crucial role in controlling lipid metabolism, inflammation, and energy balance, potentially providing therapeutic benefits for metabolic disorders and cardiovascular diseases. For example, in January 2023, the U.S-based clinical-stage pharmaceutical company Reneo Pharmaceuticals Inc. received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental drug Mavodelpar (REN001). This drug targets LCHAD deficiency, a genotype linked with long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARd, Mavodelpar aspires to enhance mitochondrial function, improve energy metabolism, and lessen symptoms related to LC-FAOD.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/fatty-acid-oxidation-disorders-faods-global-market-report

Which Is The Largest Region In The Fatty Acid Oxidation Disorders (FAODs) Market?
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in the fatty acid oxidation disorders (FAODs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Fatty Acid Oxidation Disorders (FAODs) Market?
2. What is the CAGR expected in the Fatty Acid Oxidation Disorders (FAODs) Market?
3. What Are the Key Innovations Transforming the Fatty Acid Oxidation Disorders (FAODs) Industry?
4. Which Region Is Leading the Fatty Acid Oxidation Disorders (FAODs) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.